Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
raygent.com
  • Biotechnology Sector Up 10% YTD: Post J.P.Morgan Healthcare Conference 0 comments
    Jan 20, 2014 2:15 PM | about stocks: ALKS, EXEL, PCYC

    2014 J.P.Morgan Healthcare Conference Update #4-Rayno Biopharmaceutical Picks

    Biotechnology started off with a roar and major indices were up 10% or more. Much of it can be attributed to the excitement and anticipation of the JPMorgan Conference with 10,000 attendees in San Francisco. Many are forecasting another good year for biotech but it will be hard to come close to the 62% sector return in 2013.

    As you can see below in the last two columns several stocks were up more than 20% YTD!

    Pharmacyclics (NASDAQ:PCYC) Up 33%

    Exelixis (NASDAQ:EXEL) Up 31.8%

    Achillion (NASDAQ:ACHN) up 24%

    Seattle Genetics (NASDAQ:SGEN) 20.2%

    Alkermes (NASDAQ:ALKS) Up 18.6%

    See our original recommendation dates and prices in the third and fourth columns. WE are in a hold mode with all of these picks. No new buys since Vertex (NASDAQ:VRTX) in November.

    WE will post our Diagnostics and Tools Portfolio later today.

    RAYNO Biopharmaceutical Portfolio

     

     

    2014   Original P Price Price Price % Ret Price %Ret  
    Summary   Recomm   Apr'11 Dec'12 1-Nov YTD'13 1/20/14 YTD 2014  
                         
    Achillion ACHN 3/4/13 8.6     2.53 -68 4.12 24  
    Alexion ALXN 2/2/09 35 100.8 95.4 123.4 2.26 139.71 5.1  
    Alkermes ALKS 3/22/13 23   18.5 35.6 59.29 48.23 18.6  
    Albany Mol AMRI 2/10/11 4.68 4.32 5.3 13.2 140.7 10.88 7.9  
    Astex ASTX* 12/27/11 1.63   2.7 8.5 49.48 acq    
    Amgen AMGN 2/2/09 55 54 87.4 118.7 13.1 119.15 4.4  
    Biogen BIIB 2/2/09 48.5 73.25 149 243 48.85 297.48 6.4  
    Cephalon CEPH* 2/2/09 76.5 76.92 80.18   30 acq    
                         
    Cubist CBST 2/2/09 21.5 28.35 42.4 61.9 19.2 74.56 8.3  
    Exelixis EXEL 9/2/10 3.3 11.12 4.58 4.97 1.97 8.08 31.8  
    First Trust FBT 4/15/10 37.5 41.3 46 64.6 29.6 76.24 10.1  
    Gilead GILD 2/2/09 51 42.81 72.7(s) 71 40.67 78.4 4.4  
    iShares ETF IBB 2/2/09 70.5 101.1 137.8 206 29.9 247.43 9  
    SPDR Bio XBI       86.38 119.6 23.7 156.66 20.3  
    Fido Biotech FBIOX             207 15  
    ImmunoGen IMGN 12/22/11 12.4   12.5 16.3 34.8 16.14 10  
    Optimer OPTR* 2/18/11 11.8 13.8 9.2 12.8 60 acq    
    Pharmacycl PCYC 6/8/12 38.2   58 122 47.8 140.64 33  
    Regeneron REGN 2/2/09 17.5 45.43 173 286 34.5 292 6  
    SeattleGen. SGEN 2/2/09 9.5 15.72 23.3 39 41 47.95 20.2  
    Vertex VRTX 11/15/13 62.8         82 10.5  
    ViroPharma VPHM* 2/2/09 12 20.05 22.9 39 29.4 50(acq)    
                         
    *acquired                    
                         

    Disclosure: I am long ACHN, .

    Additional disclosure: I am long Fidelity Biotechnology Fund FBIOX

    Stocks: ALKS, EXEL, PCYC
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.